Patient perspective of tardive dyskinesia: results from a social media listening study

Mallory Farrar, Leslie Lundt, Ericha Franey, Chuck Yonan, Mallory Farrar, Leslie Lundt, Ericha Franey, Chuck Yonan

Abstract

Background: Tardive dyskinesia (TD) is a persistent and potentially disabling movement disorder associated with prolonged exposure to dopamine receptor blocking agents such as antipsychotics. With the expanding use of antipsychotics, research is needed to better understand patient perspectives of TD, which clinical assessments may fail to capture. Social media listening (SML), which is recognized by the US FDA as a method that can advance ongoing efforts for more patient-focused drug development, has been used to understand patient experiences in other disease states. This is the first study to use SML analysis of unsolicited patient and caregiver insights to help clinicians understand how patients describe their symptoms, the emotional distress associated with TD, and the impact on caregivers.

Methods: In this pilot study, a comprehensive search was performed for publicly available, English-language, online content posted between March 2017 and November 2019 on social media platforms, blogs, and forums. An analytics platform (NetBase™) identified posts containing patient or caregiver experiences of assumed TD using predefined search terms. All posts were manually curated and reviewed to ensure quality and validity of the post and to further classify key symptoms, sentiments, and themes.

Results: A total of 261 posts from patients/caregivers ("patient insights") were identified using predefined search terms; 107 posts were used for these analyses. Posts were primarily from forums (47%) and Twitter (33%). Analysis of the most common sentiment-related terms (e.g. "feel" [n = 31], "worse" [n = 17], "symptom" [n = 14], "better" [n = 12]) indicated that 64% were negative, 33% were neutral, and 3% were positive. Theme analysis revealed that patients often felt angry about having TD from a medication used to treat a different condition. In addition, patients felt insecure, including feeling unaccepted by society and fear of being judged by others.

Conclusion: Although this study was limited by inherent methodological constraints (e.g., small sample size, reliance on patient self-report), the perspectives generated from analyzing social media may help convey the unmet needs of patients with TD. This analysis indicated that movement-related symptoms are the most common patient concern, resulting in strong feelings of anger and insecurity.

Keywords: Antipsychotics; Disease burden; Patient perspective; Social media listening; Tardive dyskinesia.

Conflict of interest statement

All authors are employees of Neurocrine Biosciences, Inc.

Figures

Fig. 1
Fig. 1
Selection of Posts. aSocial media platforms which did not provide public access to information/posts (e.g., Facebook) were excluded
Fig. 2
Fig. 2
Sources of Social Media Posts (N = 107)
Fig. 3
Fig. 3
TD-Related Terms from Social Media Sources. Terms are presented in descending order of mentions; a single post might include > 1 term. a. Disease Characteristics. b. Sentiments
Fig. 4
Fig. 4
Sentiment Analysis
Fig. 5
Fig. 5
Theme Analysis

References

    1. Jain R, Correll CU. Tardive dyskinesia: recognition, patient assessment, and differential diagnosis. J Clin Psychiatry. 2018;79:nu17034ah17031c. doi: 10.4088/JCP.nu17034ah1c.
    1. Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017;78:e264–e278. doi: 10.4088/JCP.16r10832.
    1. Correll CU, Kane JM, Citrome LL. Epidemiology, prevention, and assessment of tardive dyskinesia and advances in treatment. J Clin Psychiatry. 2017;78:1136–1147. doi: 10.4088/JCP.tv17016ah4c.
    1. Caroff SN, Yeomans K, Lenderking WR, Cutler AJ, Tanner CN, et al. RE-KINECT: a prospective study of the presence and healthcare burden of tardive dyskinesia in clinical practice settings. J Clin Psychopharmacol. 2020;40:259–268. doi: 10.1097/JCP.0000000000001201.
    1. Strassnig M, Rosenfeld A, Harvey PD. Tardive dyskinesia: motor system impairments, cognition and everyday functioning. CNS Spectr. 2018;23:370–377. doi: 10.1017/S1092852917000542.
    1. McEvoy JP. Psychosocial implications of tardive dyskinesia in patients with mood disorders versus schizophrenia. J Clin Psychiatry. 2019;80:NU18041BR2C. doi: 10.4088/JCP.NU18041BR2C.
    1. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Available at: . Accessed 21 Dec 2020.
    1. O'Brien CF, Jimenez R, Hauser RA, Factor SA, Burke J, Mandri D, Castro-Gayol JC. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Mov Disord. 2015;30:1681–1687. doi: 10.1002/mds.26330.
    1. Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174:476–484. doi: 10.1176/appi.ajp.2017.16091037.
    1. Fernandez HH, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017;88:2003–2010. doi: 10.1212/WNL.0000000000003960.
    1. Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4:595–604. doi: 10.1016/S2215-0366(17)30236-5.
    1. Cook N, Mullins A, Gautam R, Medi S, Prince C, Tyagi N, Kommineni J. Evaluating patient experiences in dry eye disease through social media listening research. Ophthalmol Ther. 2019;8:407–420. doi: 10.1007/s40123-019-0188-4.
    1. Cook NS, Kostikas K, Gruenberger JB, Shah B, Pathak P, Kaur VP, et al. Patients’ perspectives on COPD: findings from a social media listening study. ERJ Open Res. 2019;5:00128–02018.
    1. U.S. Department of Health and Human Services Food and Drug Administration. Patient-focused drug development: collecting comprehensive and representative input guidance for industry, Food and Drug Administration staff, and other stakeholders. Silver Springs: Center for Drug Evaluation and Research; 2020.
    1. Santos J, Palumbo F, Molsen-David E, Willke RJ, Binder L, Drummond M, et al. ISPOR code of ethics 2017 (4th edition) Value Health. 2017;20:1227–1242. doi: 10.1016/j.jval.2017.10.018.
    1. Factor SA, Remington G, Comella CL, Correll CU, Burke J, Jimenez R, et al. The effects of valbenazine in participants with tardive dyskinesia: results of the 1-year KINECT 3 extension study. J Clin Psychiatry. 2017;78:1344–1350. doi: 10.4088/JCP.17m11777.
    1. Marder SR, Singer C, Lindenmayer JP, Tanner CM, Comella CL, Verghese C, et al. A phase 3, 1-year, open-label trial of valbenazine in adults with tardive dyskinesia. J Clin Psychopharmacol. 2019;39:620–627. doi: 10.1097/JCP.0000000000001111.
    1. Fernandez HH, Stamler D, Davis MD, Factor SA, Hauser RA, Jimenez-Shahed J, et al. Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. J Neurol Neurosurg Psychiatry. 2019;90:1317–1323.
    1. Fang ML, Canham SL, Battersby L, Sixsmith J, Wada M, Sixsmith A. Exploring privilege in the digital divide: implications for theory, policy, and practice. Gerontologist. 2019;59:e1–15.
    1. Mitchell UA, Chebli PG, Ruggiero L, Muramatsu N. The digital divide in health-related technology use: the significance of race/ethnicity. Gerontologist. 2019;59:6–14. doi: 10.1093/geront/gny138.
    1. Sreeram V, Shagufta S, Kagadkar F. Role of vesicular monoamine transporter 2 inhibitors in tardive dyskinesia management. Cureus. 2019;11:e5471.
    1. Neurocrine Biosciences, Inc . Talk About TD. 2020.

Source: PubMed

3
订阅